A new platelet aggregation inhibitor which possesses hypolipemic and uricosuric properties, 2-[3-(2-thiazolylthio)phenyl]propionic acid (TPA).
In vitro, 2-[3-(2-thiazolylthio)phenyl]propionic acid (TPA) at plasma concentrations ranging from 0.02 to 1.0 microgram/ml prevents aggregation of human platelets induced by various aggregating agents. Oral administration of TPA to guinea pigs inhibits platelet aggregation; the estimated dose to reduce aggregation by 50% is 0.3 mg/kg. TPA protects rabbits against arachidonate-induced thromboembolic death (50% protection at 0.79 mg/kg i.p.). TPA is a potent hypotriglyceridemic agent in rats when present in the diet in concentrations as low as 0.003%. In chimpanzees, TPA is uricosuric at oral doses of 0.625 and 2.5 mg/kg. This rare combination of pharmacological properties suggests that TPA is a potentially useful antithrombotic agent.
D000244:Adenosine Diphosphate / Q000037:antagonists & inhibitors; D000818:Animals; D001095:Arachidonic Acids / Q000037:antagonists & inhibitors / Q000633:toxicity; D002784:Cholesterol / Q000097:blood; D003094:Collagen / Q000037:antagonists & inhibitors; D006168:Guinea Pigs; D006801:Humans; D000960:Hypolipidemic Agents; D066298:In Vitro Techniques; D008297:Male; D002679:Pan troglodytes; D010666:Phenylpropionates / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D011817:Rabbits; D051381:Rats; D013237:Stereoisomerism; D013844:Thiazoles / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood; D014528:Uricosuric Agents
D001095:Arachidonic Acids; D000960:Hypolipidemic Agents; D010666:Phenylpropionates; D013844:Thiazoles; D014280:Triglycerides; D014528:Uricosuric Agents; D000244:Adenosine Diphosphate; D003094:Collagen; D002784:Cholesterol